BACKGROUND: Epithelial carcinoma of the ovary has the highest death rate of any gynecologic malignancy in the developed world. The antigen CA-125 has been used over the past decade as a tumor marker for epithelial ovarian cancer and other cancers of coelomic epithelium. The object of this study was to see if the degree of elevation of preoperative CA-125 was related to length of survival in patients with epithelial ovarian carcinoma. METHODS: Eighty-two consecutive patients diagnosed with epithelial ovarian carcinoma were evaluated for their initial preoperative CA-125 level, time to recurrence, length of survival and level of primary debulking as well as International Federation of Gynecologists and Obstetricians stage, grade and histology. Ovarian tumors of low malignant potential were not included in the study. All patients had their initial surgery performed by one surgeon. RESULTS: Decreased length of survival was related to the degree of elevation of CA-125 prior to initial exploratory laparotomy (P = .047). The mean initial CA-125 for patients surviving five years or more (15 patients) was 899 U/mL, with an SD of +/- 1,880 U/mL, while the CA-125 for patients surviving less than five years (67 patients) was 1,978 U/mL, with an SD of +/- 1,852 U/mL (P = .02). Increased stage of disease at initial laparotomy showed a relationship to increased CA-125 (P < .0001). CONCLUSION: In epithelial ovarian carcinoma, high preoperative serum levels of CA-125 predict decreased length of survival.
BACKGROUND: Epithelial carcinoma of the ovary has the highest death rate of any gynecologic malignancy in the developed world. The antigen CA-125 has been used over the past decade as a tumor marker for epithelial ovarian cancer and other cancers of coelomic epithelium. The object of this study was to see if the degree of elevation of preoperative CA-125 was related to length of survival in patients with epithelial ovarian carcinoma. METHODS: Eighty-two consecutive patients diagnosed with epithelial ovarian carcinoma were evaluated for their initial preoperative CA-125 level, time to recurrence, length of survival and level of primary debulking as well as International Federation of Gynecologists and Obstetricians stage, grade and histology. Ovarian tumors of low malignant potential were not included in the study. All patients had their initial surgery performed by one surgeon. RESULTS: Decreased length of survival was related to the degree of elevation of CA-125 prior to initial exploratory laparotomy (P = .047). The mean initial CA-125 for patients surviving five years or more (15 patients) was 899 U/mL, with an SD of +/- 1,880 U/mL, while the CA-125 for patients surviving less than five years (67 patients) was 1,978 U/mL, with an SD of +/- 1,852 U/mL (P = .02). Increased stage of disease at initial laparotomy showed a relationship to increased CA-125 (P < .0001). CONCLUSION: In epithelial ovarian carcinoma, high preoperative serum levels of CA-125 predict decreased length of survival.
Authors: Dina Mury; Linn Woelber; Sabine Jung; Christine Eulenburg; Matthias Choschzick; Isabell Witzel; Joerg Schwarz; Fritz Jaenicke; Sven Mahner Journal: J Cancer Res Clin Oncol Date: 2011-02-23 Impact factor: 4.553
Authors: Daniel W Cramer; Allison F Vitonis; William R Welch; Kathryn L Terry; Annekathryn Goodman; Bo R Rueda; Ross S Berkowitz Journal: Gynecol Oncol Date: 2010-09-17 Impact factor: 5.482
Authors: Daniel W Cramer; Dennis J O'Rourke; Allison F Vitonis; Ursula A Matulonis; Daniel A Dijohnson; Patrick M Sluss; Christopher P Crum; Brian C-S Liu Journal: Clin Chem Date: 2010-10-13 Impact factor: 8.327
Authors: Mustafa Kemal Takal; Cem Baykal; Eralp Başer; Mustafa Derda Kaya; Polat Dursun; Ozlem Ozen; Asuman Nihan Haberal; Ali Ayhan Journal: J Turk Ger Gynecol Assoc Date: 2013-09-01
Authors: Germán González; Kornél Lakatos; Jawad Hoballah; Roberta Fritz-Klaus; Lojain Al-Johani; Jeff Brooker; Sinyoung Jeong; Conor L Evans; Petra Krauledat; Daniel W Cramer; Robert A Hoffman; W Peter Hansen; Manish S Patankar Journal: Cancers (Basel) Date: 2021-04-25 Impact factor: 6.639
Authors: Ivana Rizzuto; Chara Stavraka; Jayanta Chatterjee; Jane Borley; Thomas Glass Hopkins; Hani Gabra; Sadaf Ghaem-Maghami; Les Huson; Sarah P Blagden Journal: Int J Gynecol Cancer Date: 2015-03 Impact factor: 3.437
Authors: Kehinde Sharafadeen Okunade; Adebola A Adejimi; Ephraim O Ohazurike; Omolola Salako; Benedetto Osunwusi; Muisi A Adenekan; Aloy O Ugwu; Adaiah Soibi-Harry; Olayemi Dawodu; Adeyemi A Okunowo; Rose I Anorlu; Jonathan S Berek Journal: JCO Glob Oncol Date: 2021-01
Authors: Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice Journal: J Cancer Res Clin Oncol Date: 2010-01-16 Impact factor: 4.553